Menu
12/08/2010
UK's Breast Cancer Deaths Fall
Population-based breast cancer mortality rates in the UK have dropped steeply in the last two decades - more than in any other major European country - according to a study published on bmj.com.
These results challenge claims that survival after breast cancer is worse in the UK than elsewhere in western Europe.
The apparently poor UK survival rates are misleading because of shortcomings in the way cancers are registered in the UK, whereas the population-based mortality rates are reasonably reliable, says an accompanying editorial.
Since the late 1980s, breast cancer mortality rates have been falling in many European countries. This has been largely attributed to the combined effects of early diagnosis, including breast screening, and the effective treatment of breast cancer.
A team of researchers led by Philippe Autier from the International Prevention Research Institute in France, examined changes in breast cancer mortality rates in women living in 30 European countries from 1980 to 2006.
Using World Health Organisation data, mortality rates were calculated for all women and by age group (less than 50 years, 50-69 years and 70 years and over).
From 1989 to 2006, breast cancer mortality decreased by 20% or more in 15 European countries. In the UK, mortality rates fell by about 30%, more than in any other major European country. In France, Finland and Sweden, that have also invested much in breast screening and new cancer drugs, mortality rates decreased by 10-16%.
In central European countries, breast cancer mortality rates did not decline and even increased during the last two decades.
Women aged under 50 showed the biggest reductions in mortality rates, although screening at that age is uncommon. This may reflect better targeting of effective treatments, suggest the authors. They also suggest that the sustained decline observed in many countries seems to indicate that breast cancer mortality will continue to decrease beyond 2006.
The authors call for better data collection to help understand the variations in breast cancer mortality across Europe and action to reduce avoidable breast cancer mortality in central European countries.
In an accompanying editorial, Valerie Beral and Richard Peto, at the University of Oxford, point out that cancer registration in the UK is known to be incomplete and that defects in these data make cancer survival rates appear significantly worse than they really are. By contrast, the registration of death is complete, deaths from breast cancer are well recorded (except at old age), and so population-based mortality trends in middle age are fairly reliable.
They conclude that the rapid decline in UK population-based breast cancer mortality rates in middle age (see graph - link below) are valid and that failure to make proper allowances for the shortcomings of cancer registration data “may well have led to misleading claims about the supposed inferiority of UK cancer treatment services in general."
(GK/BMcC)
These results challenge claims that survival after breast cancer is worse in the UK than elsewhere in western Europe.
The apparently poor UK survival rates are misleading because of shortcomings in the way cancers are registered in the UK, whereas the population-based mortality rates are reasonably reliable, says an accompanying editorial.
Since the late 1980s, breast cancer mortality rates have been falling in many European countries. This has been largely attributed to the combined effects of early diagnosis, including breast screening, and the effective treatment of breast cancer.
A team of researchers led by Philippe Autier from the International Prevention Research Institute in France, examined changes in breast cancer mortality rates in women living in 30 European countries from 1980 to 2006.
Using World Health Organisation data, mortality rates were calculated for all women and by age group (less than 50 years, 50-69 years and 70 years and over).
From 1989 to 2006, breast cancer mortality decreased by 20% or more in 15 European countries. In the UK, mortality rates fell by about 30%, more than in any other major European country. In France, Finland and Sweden, that have also invested much in breast screening and new cancer drugs, mortality rates decreased by 10-16%.
In central European countries, breast cancer mortality rates did not decline and even increased during the last two decades.
Women aged under 50 showed the biggest reductions in mortality rates, although screening at that age is uncommon. This may reflect better targeting of effective treatments, suggest the authors. They also suggest that the sustained decline observed in many countries seems to indicate that breast cancer mortality will continue to decrease beyond 2006.
The authors call for better data collection to help understand the variations in breast cancer mortality across Europe and action to reduce avoidable breast cancer mortality in central European countries.
In an accompanying editorial, Valerie Beral and Richard Peto, at the University of Oxford, point out that cancer registration in the UK is known to be incomplete and that defects in these data make cancer survival rates appear significantly worse than they really are. By contrast, the registration of death is complete, deaths from breast cancer are well recorded (except at old age), and so population-based mortality trends in middle age are fairly reliable.
They conclude that the rapid decline in UK population-based breast cancer mortality rates in middle age (see graph - link below) are valid and that failure to make proper allowances for the shortcomings of cancer registration data “may well have led to misleading claims about the supposed inferiority of UK cancer treatment services in general."
(GK/BMcC)
Related UK National News Stories
Click here for the latest headlines.
17 October 2005
Breast cancer can cost ‘thousands’
Breast cancer can cost sufferers thousands of pounds, a survey by a leading cancer charity has revealed. Macmillan Cancer Relief surveyed 50 cancer patients and found that, on average, they spent almost £2,000 on extra costs during their treatment.
Breast cancer can cost ‘thousands’
Breast cancer can cost sufferers thousands of pounds, a survey by a leading cancer charity has revealed. Macmillan Cancer Relief surveyed 50 cancer patients and found that, on average, they spent almost £2,000 on extra costs during their treatment.
29 October 2003
Saturated fats could 'slightly increase' breast cancer risk
Eating large amounts of saturated fat could "slightly increase" the risk of breast cancer, according to a review published in the British Journal of Cancer.
Saturated fats could 'slightly increase' breast cancer risk
Eating large amounts of saturated fat could "slightly increase" the risk of breast cancer, according to a review published in the British Journal of Cancer.
27 June 2014
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
16 April 2012
Celebs Support Early Detection Drive
Sharon Osbourne and football legends Kenny Dalglish and Sir Alex Ferguson are among the celebrities backing a drive to increase the early detection of cancer.
Celebs Support Early Detection Drive
Sharon Osbourne and football legends Kenny Dalglish and Sir Alex Ferguson are among the celebrities backing a drive to increase the early detection of cancer.
12 April 2006
Breast cancer patient wins Herceptin court battle
A breast cancer patient has won an appeal to receive the drug Herceptin on the NHS. Ann Marie Rogers, 54, from Swindon went to the Court of Appeal after the High Court ruled that Swindon Primary Care Trust had not acted unlawfully in refusing to give her the drug.
Breast cancer patient wins Herceptin court battle
A breast cancer patient has won an appeal to receive the drug Herceptin on the NHS. Ann Marie Rogers, 54, from Swindon went to the Court of Appeal after the High Court ruled that Swindon Primary Care Trust had not acted unlawfully in refusing to give her the drug.
-
Northern Ireland WeatherToday:A showery start with outbreaks most frequent north of Lough Neagh and through the morning, before dwindling during the afternoon as the northwest breezes ease and brighter spells of weak sunshine prosper. Maximum temperature 8 °C.Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
